With a market cap of $309.7 billion, AbbVie Inc. (ABBV) is a research-based biopharmaceutical company, engaged in the ...

Best Stocks for 15 Years. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

AbbVie on Thursday cut its 2025 adjusted profit forecast as the drugmaker expects to incur $248 million in acquisition ...

Highlights,Market sentiment surrounding AbbVie (NYSE:ABBV) has shifted following rating changes and price objective ...

Discover AbbVie's strong performance, with immunology growth and undervaluation despite challenges. Click here to read an ...

The 340B program requires drugmakers who want to participate in Medicaid and Medicare to discount their prices for hospitals, ...

communities and shareholders who depend on us." Miles D. White, chairman and chief executive officer, Abbott, in a press release from the 2nd January 2013. According to AbbVie, the company has ...

AbbVie (NYSE:ABBV) has been actively advancing its oncology portfolio with recent presentations at the AACR Annual Meeting, ...

AbbVie has beaten Wall Street's revenue estimates ... Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors ...

SAN DIEGO, CA / ACCESS Newswire / April 9, 2025 / Robbins LLP reminds stockholders that a class action was filed against ...